Clinical Trial Update: A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating suvorexant (MK-4305) for treating insomnia disorder in adults with opioid use disorder. The study is currently in recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia
• Opioid Use Disorder

Drugs mentioned

• Suvorexant (suvorexant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Insomnia | Phase 3 | Status: RECRUITING